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ORIGINAL ARTICLECorrection of Hair Shaft Defects through
Allele-Specific Silencing of Mutant Krt75
Ying Liu1, Elizabeth R. Snedecor2,3, Xu Zhang1, Yanfeng Xu1, Lan Huang1, Evan C. Jones4,
Lianfeng Zhang1, Richard A. Clark4, Dennis R. Roop5, Chuan Qin1 and Jiang Chen1,2,4,5Dominant mutations in keratin genes can cause a number of inheritable skin disorders characterized by
intraepidermal blistering, epidermal hyperkeratosis, or abnormalities in skin appendages, such as nail plate
dystrophy and structural defects in hair. Allele-specific silencing of mutant keratins through RNA interference is
a promising therapeutic approach for suppressing the expression of mutant keratins and related phenotypes in
the epidermis. However, its effectiveness on skin appendages remains to be confirmed in vivo. In this study, we
developed allele-specific small interfering RNAs capable of selectively suppressing the expression of a mutant
Krt75, which causes hair shaft structural defects characterized by the development of blebs along the hair shaft in
mice. Hair regenerated from epidermal keratinocyte progenitor cells isolated from mutant Krt75 mouse models
reproduced the blebbing phenotype when grafted in vivo. In contrast, mutant cells manipulated with a lentiviral
vector expressing mutant Krt75-specific short hairpin RNA (shRNA) persistently suppressed this phenotype. The
phenotypic correction was associated with a significant reduction of mutant Krt75mRNA in the skin grafts. Thus,
data obtained from this study demonstrated the feasibility of utilizing RNA interference to achieve durable
correction of hair structural phenotypes through allele-specific silencing of mutant keratin genes.
Journal of Investigative Dermatology (2016) 136, 45-51; doi:10.1038/JID.2015.375INTRODUCTION
Keratins are the most abundant form of intermediate filament
proteins in keratinocytes. Mutations in keratins are respon-
sible for the majority of inheritable epidermal disorders, such
as epidermolysis bullosa, epidermolytic ichthyosis (formerly
known as epidermolytic hyperkeratosis), Ichthyosis bullosa of
Siemens, and pachyonychia congenita, which are charac-
terized by intraepidermal blistering and generalized or pal-
moplantar hyperkeratosis (Lane and McLean, 2004; Uitto
et al., 2007). Mutations in hair follicleerelated keratins can
cause hair abnormalities, such as monilethrix, autosomal
dominant woolly hair, and pseudofolliculitis barbae (Harel
and Christiano, 2012; Schweizer et al., 2007).
Most disease-causing mutations in keratins are dominant-
negative mutations, in which the mutant keratin gene prod-
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Christiano, 2012; Knobel et al., 2015; McLean and Moore,
2011; Uitto et al., 2007). Suppressing the production of
mutant keratins through an allele-specific inhibition of
mutant keratin genes may be effective in correcting associ-
ated phenotypes (Knobel et al., 2015; McLean and Moore,
2011).
RNA interference (RNAi) has been successfully utilized in
achieving allele-specific inhibition of mutant keratin genes.
For example, mutant-specific small interfering RNAs (siRNAs)
against disease-causing mutations in the KRT9, KRT5, and
KRT6A genes were demonstrated to be capable of inhibiting
the expression of these mutant keratins in vitro and in vivo
(Atkinson et al., 2011; Hickerson et al., 2008, 2011b; Leslie
Pedrioli et al., 2012). Moreover, an intraepidermal injection
of siRNA was capable of suppressing plantar hyperkeratosis
in pachyonychia congenita (Leachman et al., 2010), con-
firming the therapeutic value of this approach for correcting
phenotypes associated with keratin mutations. Whether this
therapeutic strategy can achieve lasting therapeutic benefit is
yet to be determined in vivo.
KRT75, formerly known as K6HF, is expressed in the
companion layer of the hair follicle and the medulla of the
hair shaft (Winter et al., 1998; Wojcik et al., 2001). Hetero-
zygous mutations in KRT75 (A12T and E337K) are associated
with the development of pseudofolliculitis barbae and loose
anagen hair syndrome, respectively (Chapalain et al., 2002;
Winter et al., 2004). Moreover, the decreased expression of
KRT75 was also observed in cicatricial alopecia (Chapalain
et al., 2002; Sperling et al., 2010). Genetically engineered
mutant mice (Krt75tm1Der) expressing a mutant form of Krt75
(N159del) developed hair shaft blebbing (Chen et al., 2008).
Moreover, mutations in Krt75 also contribute to the devel-
opment of frizzle feathers in chicken (Ng et al., 2012) andestigative Dermatology. www.jidonline.org 45
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46altered enamel structure of human teeth (Duverger et al.,
2014). These observations demonstrated an important role
of KRT75 in maintaining the structural integrity of the hair
and other skin appendages.
In this study, we demonstrated that hair follicles regener-
ated with mutant Krt75 epidermal keratinocyte progenitor
cells were able to reproduce the hair shaft blebbing pheno-
type in vivo. Suppressing mutant Krt75 expression by shRNA
effectively suppressed the development of this hair shaft
phenotype. Thus, this study established the feasibility of using
ex vivo modified epidermal keratinocyte progenitor cells to
prevent structural abnormalities of the hair.
RESULTS
Development of allele-specific siRNA for mutant Krt75
siRNAs are capable of selectively silencing mutant keratin
genes, such as KRT6A, KRT5, and KRT9, at the resolution of
single base pairs. In this study, we examined whether siRNA
is able to suppress a three-base-pair in-frame deletion
(c.545_547del (p.N159del)) mutation in the mouse Krt75
gene (Chen et al., 2008). Nineteen candidate siRNAs for the
mutant Krt75 were engineered and tested by allele-specific
qRT-PCR (Supplementary Figure S1 online).
Two candidate siRNAs, siN159D-5 and siN159D-6 (15
nM), demonstrated a strong (>70%) inhibition of the mutant
Krt75, but a moderate (<45%) effect on wild-type Krt75
(Figure 1b). In contrast, negative control siRNA (15 nM) had
no effect on the expression of Krt75 and a positive control
siRNA (15 nM) indiscriminately suppressed the expression of
both wild-type and mutant Krt75 (Figure 1b). When evalu-
ated at variable concentrations, both siN159D-5 and
siN159D-6 demonstrated the robust inhibitory effect on the
mutant Krt75 (Figure 1c and d), but siN159D-6 is more se-
lective for mutant, but not wild-type Krt75 (Figure 1d). Thus,
siN159D-6 was selected for future experiments. The scram-
bled sequence of siN159D-6 was used as negative control
(siN159D-6S).
To achieve long-term inhibition in cells in vivo, siN159D-6
and siN159D-6S were cloned as hairpin shRNAs into pLVX-
ShRNA2 lentiviral vectors (Supplementary Figure S2 online).
Lentiviral vectors are not only able to efficiently infect large
amounts of keratinocyte progenitor cells, but are also able to
integrate into the cell’s genome, thereby achieving contin-
uous expression of shRNA. Lentiviral vectors expressing
shN159D-6 or shN159D-6S were able to efficiently infect
HEK293T and primary keratinocytes (greater than 83.6% and
82.0%, respectively) without noticeable adverse effects on
cell growth and morphology in vitro (Supplementary
Figure S2).
Mutant Krt75-specific shRNA suppresses hair shaft
phenotype
To establish an in vivo model suitable for testing therapeutic
effectiveness of RNAi, mutant Krt75 keratinocyte progenitor
cells were isolated from homozygous mutant Krt75 mice
(Krt75tm1Der/Krt75tm1Der) and grafted onto immune deficient
nude mice to regenerate skin and hair follicles in vivo.
Mutant cells efficiently regenerated skin and hair and, most
importantly, the majority of hair shafts (85.2  5.4%) con-
tained the characteristic bleb phenotype as observed in the
homozygous mutant Krt75 mice (Figure 2a andJournal of Investigative Dermatology (2016), Volume 136Supplementary Figure S3 online). This result demonstrated
that the grafting of ex vivo cultured mutant keratinocyte
progenitor cells can be used as a model to test therapeutic
intervention.
To determine whether mutant Krt75-specific shRNA was
able to suppress hair shaft defects regenerated in skin grafts,
homozygous mutant Krt75 keratinocytes were infected with
lentiviral vectors before grafting. One month later, hair was
regenerated. Analyses of hair regenerated with lentiviral
vectoreinfected cells by light and transmission electron mi-
croscopy demonstrated that shN159D-6 was able to robustly
suppress the formation of blebs in the hair shaft such that only
34.6  7.6% of hair shafts contained bulbous lesions
(Figure 2b and d, and Supplementary Figure S3). In contrast,
scrambled shRNA (shN159D-6S) had no effect on suppress-
ing the hair phenotype (Figure 2c and d, and Supplementary
Figure S3), and the majority (78.6  4.0%) of hair shafts re-
generated with scrambled shRNA-treated cells contained
defective hair shafts (Figure 2d).
Because some hairs contain more than one bleb, the
effectiveness of shRNA was also evaluated based on the
number of bulbous lesions per hair shaft. Affected hair shafts
regenerated with shN159D-6 lentiviral vectoreinfected cells
contained 0.97  0.11 bulbous lesions (Supplementary
Figure S4 online), whereas affected hair shafts regenerated
with noninfected cells and scrambled (shN159D-6S) lenti-
viral vectoreinfected cells contained 1.43  0.28 and 1.44 
0.23 blebs per hair shaft one month after grafting, respec-
tively (P < 0.01, Supplementary Figure S4). Collectively,
these findings demonstrated that the mutant Krt75-specific
shRNA was not only able to suppress the frequency of
defective hair shafts, but also ameliorate the severity of
affected hair.
Mutant-specific shRNA suppresses the expression of the
mutant Krt75 in vivo
To determine whether suppression of the hair phenotype was
associated with suppression of mutant Krt75 expression, qRT-
PCR was performed on skin grafts. The relative expression
level of the mutant Krt75 was normalized to its level in
noninfected control grafts. A marked reduction in the level of
mutant Krt75 transcripts (37.3  6.9%) was observed in grafts
regenerated with shN159D-6 lentiviral vectoreinfected cells
(Figure 3a). In comparison, the expression level of the mutant
Krt75 (94.2  11.6%) in grafts regenerated with scrambled
shRNA was almost identical to that in controls (Figure 3a).
The expression of a number of keratin genes that are
expressed in the epidermis and hair follicles (Krt5, Krt14, and
Krt1) or related to Krt75 (Krt6a and Krt17) was evaluated.
Results showed that the expression profiles of these genes
were not affected in skin grafts regenerated with lentiviral
vectors expressing either mutant Krt75-specific shRNA or
scrambled shRNA. These results suggest that lentiviral-
mediated transcription suppression of a mutant form of ker-
atin is likely capable of achieving high specificity in vivo.
Lentiviral-mediated ex vivo modification of keratinocyte
progenitor cells exhibit a sustained suppression of
blebbing phenotype
To further determine whether phenotypic suppression was
sustainable, skin grafts were analyzed 3 months after grafting.
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Figure 1. Mutant Krt75-specific
siRNA. (a) Sequences of wild-type and
c.545_547del (p.N159del) Krt75 and
candidate siRNAs for the mutant
Krt75. (b) Relative expression levels of
wild-type and mutant Krt75 in
HEK293T cells cotransfected with
wild-type and mutant Krt75 siRNA
(15 nM) by quantitative RT-PCR.
Blank, cells transfected with Krt75
expression plasmids without siRNA;
NC, cells transfected with negative
control (a fragment of inverted beta-
galactosidase sequence) siRNA;
Krt75-siRNA, a commercially
available siRNA against Krt75. (c, d)
Relative expression levels of wild-type
and mutant Krt75 in cells transfected
with 015 nM siN159D-5 and
siN159D-6 siRNAs, as normalized to
GAPDH. All experiments were carried
out in triplicates in a minimum of
three independent experiments.
GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; siRNA, small
interfering RNA.
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Gene Therapy for Mutant Krt75We estimate that hair follicles analyzed 3 months after
grafting underwent two more hair cycles than those harvested
at 1 month after grafting. First, all experimental groups dis-
played no evidence of hair loss at 3 months (Supplementary
Figure S5 online). Examination of hair shafts revealed that the
proportion of phenotypic hair shafts in control and shRNA-
treated groups was consistent with those harvested at 1
month after grafting (Supplementary Figure S5). Specifically,
noninfected control and scrambled shRNA-infected kerati-
nocytes regenerated hair shafts with 84.7  3.1% and
81.2  5.3% defects, respectively (Supplementary Figure S5).
In contrast, hair regenerated with cells infected with
shN159D-6 contained 37.0  9.0% defective hair shafts(Supplementary Figure S5). Thus, hair regenerated with
shN159D-6-treated cells harbored significantly reduced
numbers of defective shafts (P < 0.05, Supplementary
Figure S5). These results suggested that lentiviral vectore
mediated manipulation of ex vivo cultured keratinocytes was
able to maintain a lasting suppression of hair shaft pheno-
types, likely due to the integration capability of lentiviral
vectors and continuous expression of encoded shRNA.
RNAi can suppress phenotypes associated with heterozygous
mutant Krt75
So far, the therapeutic effect of shN159D-6 was examined in
homozygous mutant Krt75 cells. However, disease-causingwww.jidonline.org 47
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Figure 2. Phenotypes of hair regenerated with shRNA-modified homozygous mutant Krt75 keratinocyte progenitor cells. (ac) Representative gross
appearance, low and high power images of hair regenerated with noninfected cells. Control (a), shN159D-6 lentiviral vectoreinfected cells (b), and scrambled
(shN159D-6S) lentiviral vectoreinfected cells (c) at one month of grafting. Arrows point to bulbous lesions (blebs) along the hair shaft. (d) Quantification of hair
shafts containing blebs. *P < 0.05. Scale bar ¼ 250 mm.
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48mutations in keratin genes are predominantly heterozygous
mutations (Harel and Christiano, 2012; Lane and McLean,
2004; Uitto et al., 2007), including those in KRT75
(Chapalain et al., 2002; Winter et al., 1998). To determine
whether the RNAi is capable of suppressing phenotypes
associated with heterozygous mutations, hair was regener-
ated with epidermal keratinocyte progenitor cells obtained
from heterozygous mutant Krt75 mice (Krt75þ/Krt75tm1Der).
Hair regenerated with heterozygous mutant Krt75 cells
contained 53.8 10.4% bulbous hair shafts (Figure 4a and d).
In contrast, hair regenerated with heterozygous mutant cells
treated with shRNAD-6 contained only 20.9 5.8% defective
hair shafts, which was significantly reduced in comparison to
noninfected and scrambled shRNA-treated (49.3  8.9)
groups (P < 0.05, Figure 4).
Heterozygous mutant cells express both wild-type and
mutant Krt75, permitting the evaluation of the transcriptional
levels of both transcripts. Quantitative RT-PCR on wild-type
Krt75 demonstrated comparable expression levels of wild-
type Krt75 in all experimental groups (noninfected control,
100.0  6.7; shN159D-6, 89.2  6.1; shN159D-6S, 88.1 
7.0, Figure 4e). In contrast, the expression of the mutant Krt75
was selectively suppressed in shN159D-6-treated group
(37.5  3.3) but not in noninfected or scrambled controls
(100.0  8.4 and 87.4  8.5, respectively, Figure 4e). These
results suggest that suppressing the expression of the mutant
Krt75 in heterozygous mutant cells is able to ameliorate the
blebbing phenotype of the hair.Journal of Investigative Dermatology (2016), Volume 136DISCUSSION
RNAi-mediated ex vivo therapy is among the most promising
approaches for correcting phenotypes associated with
dominant mutations in keratin genes in skin (Uitto, 2012).
Although keratins are redundantly expressed in keratinocytes
and considerable homology exists among keratin genes,
recent progress has demonstrated the feasibility of engineer-
ing allele-specific siRNAs that are capable of suppressing
mutant keratin expression (Atkinson et al., 2011; Hickerson
et al., 2008; Leslie Pedrioli et al., 2012). More importantly,
evidence obtained from a number of in vitro and in vivo
models, and a single patient, split-body, vehicle-controlled
phase I clinical trial support the usefulness of utilizing siRNA
to suppress mutant keratin expression (Hickerson et al.,
2011a; Leachman et al., 2010; Leslie Pedrioli et al., 2012).
In this study, we developed siRNAs capable of specifically
inhibiting a dominant mutant form of Krt75, and confirmed
the effectiveness of RNAi-based ex vivo therapy at both the
phenotypic and molecular levels in mice. Data obtained from
this study not only demonstrated the feasibility of perma-
nently suppressing the expression of mutant keratins, but also
provided an example of correcting structural hair defects with
ex vivo modified epidermal keratinocyte progenitor cells
in vivo.
Models capable of mimicking skin disorders at both
phenotypic and genetic levels may serve as important tools in
testing novel therapeutics for inheritable skin disorders. The
mouse model utilized in this study is a knock-in model. It
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∗ ∗ Figure 3. Gene expression in skingrafts regenerated with shRNA-
modified homozygous mutant Krt75
keratinocyte progenitor cells. (a)
Relative expression level of mutant
Krt75 (Krt75-N159del) in grafts
regenerated with ex vivo cultured
cells (as described in Figure 2) by qRT-
PCR 1 month after grafting. (b)
Relative expression levels of Krt1,
Krt5, Krt6a, Krt14, and Krt17 by qRT-
PCR in skin grafts described in (a). All
experiments were carried out in
triplicates in a minimum of three
independent experiments. *P < 0.05.
Y Liu et al.
Gene Therapy for Mutant Krt75contains a mutation analogous to one found in the KRT6A
gene in patients with pachyonychia congenita, in its endog-
enous Krt75 locus (Chen and Roop, 2008). This mouse model
represents genetic changes that occur in most keratin
mutation-related disorders. Therefore, it may serve as an ideal
preclinical model in performing proof-of-principle experi-
ments pertinent to the development of therapeutics for dis-
orders caused by keratin mutations.
The mutation targeted in this study is an in-frame three-base-
pair deletionmutation. It is analogous to a commonmutation in
the KRT6A gene (c.513_515del (p.N171del), which is also re-
ported as (c.516_518del (p.N172del) as the codon 171 and 172
are identical) in patients with pachyonychia congenita (Smith
et al., 2005; Wilson et al., 2014). Because sequences flanking
this site are almost identical between themouseKrt75 gene and
human KRT6A gene, data obtained from this study strongly
suggest that it is feasible to specifically target this mutation in
human KRT6A. In fact, potent siRNAs were previously devel-
oped for a missense mutation (c.513C>A (p.N171K)) and the
analogous c.513_515del mutation in KRT6A (Hickerson et al.,
2006, 2011b). Interestingly, the most potent and selective
siRNA for the analogous deletion in mouse Krt6a (N159del) or
the human KRT6A (N171del) target the same region (D6 in
Figure 1c or Hickerson et al., 2006, respectively). Thus, these
findings collectively support the rationale of using RNAi to
suppress the disease-causing mutant allele.
Mutations in a number of genes involved in inheritable hair
disorders cause structural defects in the hair shaft (Harel and
Christiano, 2012). Pertinent to this study, mutations in KRT75
are linked to loose anagen hair syndrome (Chapalain et al.,
2002) and pseudofolliculitis barbae (Winter et al., 2004). It
is postulated that KRT75 is important for maintaining the
integrity of the keratin intermediate filament network in
companion layer cells where it is expressed. Mutations in
KRT75 likely destabilize endogenous keratin filaments.
When compounded by mechanical stress, such as combing
and shaving, the mutant KRT75 is likely to lead to the
development of hair phenotypes. Data obtained from this
study suggest that silencing the mutant KRT75 may amelio-
rate hair phenotypes through restoring the stability of the
endogenous keratin intermediate filament network in com-
panion layer keratinocytes.
Although siRNA is highly efficient and specific in silencing
mutant keratins and, as this study demonstrated, ex vivotherapy may achieve long-term phenotypic improvement,
safety concerns associated with lentiviral vectors prevented
the use of lentiviral vectoremediated delivery of shRNA in
clinical settings. The development of robust delivery systems
through which therapeutic siRNA oligonucleotides can be
readily delivered to the site in need of treatment may provide
a straightforward and safe, albeit transient, solution for cor-
recting associated phenotypes.
MATERIALS AND METHODS
Design of mutant Krt75-specific siRNA
A total of 19 possible siRNAs against the previously reported mutant
Krt75 (c.545_547 (p.N159del)) (Chen et al., 2008) were designed
and synthesized (Thermo Fisher, Shanghai, China) (Figure 1a). Syn-
thetic siRNA duplexes are 21-mers containing two uracyl (U)
nucleotide overhangs at the 30-end of the target sequences, desig-
nated consecutively from siN159D-1 to siN159-19 (Figure 1a). A
nonspecific siRNA that contains the inverted beta-galactosidase
sequence was used as a negative control. A commercial siRNA
(SASI_Mm01_00158646, Sigma-Aldrich, St. Louis, MO) directed
against the mouse Krt75 gene was used as positive control.
Cell culture and transient transfection
HEK293T cells, which do not express endogenous KRT75, were
maintained in DMEM (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (Invitrogen) at 37 C in a 5% CO2 humid-
ified incubator. The day before transfection, cells were seeded in six-
well plates at 2.5  105 cells per well. Equal amounts (0.5 mg) of
wild-type and mutant Krt75 expression plasmids (Chen et al., 2008)
were cotransfected with each siRNA (515 nM) using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s instructions. Cells
were harvested 48 hours later for analyses.
Quantitative RT-PCR
Total RNA was extracted from cells or graft tissues with Trizol
(Invitrogen). After DNase (RQ1, Promega, Madison, WI) treatment,
250 ng mRNA was reverse transcribed to cDNA with a SuperScript
First-Strand Synthesis System (Invitrogen). cDNA (15 ng) was used in
quantitative PCR.
Quantitative real-time PCR for wild-type and mutant Krt75 was
performed with an identical primer pair (GeneCore Bio-
Technologies, Shanghai, China) (Supplementary Figure S1). Two
minor groove binder probes for allelic-specific assays for wild-type
and N159del Krt75 were designed with Primer Express Software
(Applied Biosystems v2.0, Thermo Fisher, Waltham, MA) andwww.jidonline.org 49
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Figure 4. Phenotype and gene expression in skin grafts regenerated with shRNA-modified heterozygous mutant Krt75 keratinocyte progenitor cells. (ac)
Representative hair phenotypes of hair regenerated with control and lentiviral vectoreinfected cells (as described in Figure 2) at 1 month of grafting. Arrows
point to bulbous lesions (blebs) along the hair shaft. (d) Quantification of hair shafts containing blebs. (e) Relative expression level of wild-type (Krt75-WT) and
mutant Krt75 (Krt75-N159Del) in skin grafts described in (a). *P < 0.05. Scale bar ¼ 250 mm.
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50labeled with FAM and HEX, respectively (GeneCore Bio-
Technologies) (Supplementary Figure S1). Quantitative real-time
PCR was carried out on an ABI 7500 thermal cycler (Applied Bio-
systems 7500 Fast Dx, Thermo Fisher). Mouse beta-actin (b-actin,
FAM-MGB, Life Technologies, Grand Island, NY) was used
as endogenous control. All experiments were carried out in tripli-
cates in a minimum of three independent experiments. Data
were analyzed with the standard curve method. Quantification of
Krt1, Krt5, Krt6a, Krt14, and Krt17 was performed with specific
TaqMan assays (Krt1, Mm00492992_g1; Krt5, Mm01305291_g1,
Krt6a, Mm00833464_g1; Krt14, Mm00495207_m1; Krt17,
Mm00495207_m1, Life Technologies). Gapdh (Mm99999915_g1,
Life Technologies) was used as an internal control. The DDCt method
was used for analyses.
Lentiviral vector construction and production
The shRNAs encoding siN159D-6 and scrambled siRNA (siN159D-
6S) were cloned into pLVX-ShRNA lentiviral vectors (Clontech,
Mountain View, CA) between Pst I and BamH I sites (Supplementary
Figure S2). The lentiviral vectors were produced in 293T cells as
described elsewhere (Yasuda et al., 2013). Viral vectors wereJournal of Investigative Dermatology (2016), Volume 136dissolved in serum-containing medium, aliquoted in single-use vials,
and stored at 80 C.Primary keratinocyte culture
Primary keratinocytes were isolated from newborn mice as
described previously (Lichti et al., 2008). Specifically, skins of con-
trol or mutant Krt75 pups (Chen et al., 2008) were incubated with
dispase II (Roche, Indianapolis, IN) to separate the epidermis.
Epidermal sheets were then digested with 0.25% trypsin (Life
Technologies) to release keratinocytes. The keratinocyte suspension
was then cleared through filtration and centrifugation. Keratinocytes
were then plated in 10 cm dishes with a fibroblast-conditioned
medium (Yuspa et al., 1986).
HEK293T or primary keratinocytes were infected with lentiviral
vectors as described previously (Yasuda et al., 2013). Briefly, cells
growing at approximately 20e30% confluency were treated with
8 ml/ml polybrene (Sigma-Aldrich) and infected with concen-
trated lentiviral vectors overnight. Subsequently, cells were
cultured in complete growth medium until harvested for analyses
or grafting.
Y Liu et al.
Gene Therapy for Mutant Krt75Keratinocyte grafting and hair regeneration
Keratinocyte grafting was performed as described previously (Dai
et al., 2011). Specifically, approximately 1  106 keratinocytes
infected with lentiviral vector were mixed with 2  106 primary fi-
broblasts freshly isolated from newborn pups, and seeded in grafting
chamber on the backs of nude (Foxn1/) mice. Three weeks later,
hair grew out from the graft site. All procedures related to mice were
approved by IACUC of the Institute of Laboratory Animal Science
and Stony Brook University.
Microscopy
Hair plucked from skin grafts or clipped with scissors was used for
light microscopy examination. A minimum of 100 hairs of each
experimental group were examined under stereoscope. A hair shaft
containing one or more characteristic blebs was recorded as de-
fectives. Scanning electron microscopy was carried out as described
previously (Chen et al., 2008). Skin grafts were processed without
any manipulation on the hair. A TM1000 scanning electron micro-
scope (Hitachi High-Technologies, Tokyo, Japan) was used for
imaging.
Statistical analyses
All quantifications are presented as mean  SD. Student’s t-test was
used for statistical analysis. P < 0.05 was considered statistically
significant.
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